ÁNGEL
CUESTA MARTÍNEZ
Profesor ayudante doctor
Centro de Investigaciones Biológicas
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigaciones Biológicas (9)
2023
-
Mutation in Chek2 triggers von Hippel-Lindau hemangioblastoma growth
Acta Neurochirurgica, Vol. 165, Núm. 12, pp. 4241-4251
2022
-
A Novel Splicing Mutation in the ACVRL1/ALK1 Gene as a Cause of HHT2
Journal of Clinical Medicine, Vol. 11, Núm. 11
-
Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
Journal of Clinical Medicine, Vol. 11, Núm. 15
-
The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases
International Journal of Molecular Sciences, Vol. 23, Núm. 8
2020
-
CLN5 in heterozygosis may protect against the development of tumors in a VHL patient
Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1
-
Review of pharmacological strategies with repurposed drugs for hereditary hemorrhagic telangiectasia related bleeding
Journal of Clinical Medicine, Vol. 9, Núm. 6, pp. 1-22
-
Targeting β2-adrenergic receptors shows therapeutical benefits in clear cell renal cell carcinoma from von Hippel–Lindau disease
Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-30
2019
-
Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: Phase III clinical trial
BMJ Open Ophthalmology, Vol. 4, Núm. 1
-
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease
Scientific Reports, Vol. 9, Núm. 1